GB2460672A — Cancer medication using cannabinoids in combination with non-cannabinoids
Assigned to GW Pharma Ltd · Expires 2009-12-09 · 16y expired
What this patent protects
The invention relates to the use of one or more cannabinoids, particularly tetrahydrocannabinol (THC) and/or cannabidiol (CBD) in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the can…
USPTO Abstract
The invention relates to the use of one or more cannabinoids, particularly tetrahydrocannabinol (THC) and/or cannabidiol (CBD) in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (G B M). The non-cannabinoid chemotherapeutic agent maybe a selective estrogen receptor modulator (SERM) or an alkylating agent.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.